Luz-Veiga Mariana, Azevedo-Silva João, Fernandes João C
CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4169-005 Porto, Portugal.
Amyris Bio Products Portugal, Unipessoal Lda, 4169-005 Porto, Portugal.
Pharmaceuticals (Basel). 2023 Jan 20;16(2):155. doi: 10.3390/ph16020155.
The phytocannabinoid cannabidiol (CBD) is receiving increasing attention due to its pharmacological properties. Although CBD is extracted from , it lacks the psychoactive effects of Δ9-tetrahydrocannabinol (THC) and has become an attractive compound for pharmacological uses due to its anti-inflammatory, antioxidant, anticonvulsant, and anxiolytic potential. The molecular mechanisms involved in CBD's biological effects are not limited to its interaction with classical cannabinoid receptors, exerting anti-inflammatory or pain-relief effects. Several pieces of evidence demonstrate that CBD interacts with other receptors and cellular signaling cascades, which further support CBD's therapeutic potential beyond pain management. In this review, we take a closer look at the molecular mechanisms of CBD and its potential therapeutic application in the context of cancer, neurodegeneration, and autoimmune diseases.
植物大麻素大麻二酚(CBD)因其药理特性而受到越来越多的关注。尽管CBD是从[具体来源未提及]中提取的,但它缺乏Δ9-四氢大麻酚(THC)的精神活性作用,并且由于其抗炎、抗氧化、抗惊厥和抗焦虑潜力,已成为一种有吸引力的药用化合物。参与CBD生物学效应的分子机制不仅限于其与经典大麻素受体的相互作用,从而发挥抗炎或止痛作用。多项证据表明,CBD与其他受体和细胞信号级联相互作用,这进一步支持了CBD在疼痛管理之外的治疗潜力。在这篇综述中,我们更深入地探讨了CBD的分子机制及其在癌症、神经退行性疾病和自身免疫性疾病背景下的潜在治疗应用。